LIFEVANTAGE CORP Gain (Loss) on Derivative Instruments, Net, Pretax
LIFEVANTAGE CORP (LFVN) reported Gain (Loss) on Derivative Instruments, Net, Pretax of $0 for the 12-month period ending 2014-06-30, per its 10-K filed 2014-09-10.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2014-09-10
- LIFEVANTAGE CORP gain (loss) on derivative instruments, net, pretax for the quarter ending 2013-06-30 was $0.00.
- LIFEVANTAGE CORP gain (loss) on derivative instruments, net, pretax for the quarter ending 2013-03-31 was $0.00.
- LIFEVANTAGE CORP gain (loss) on derivative instruments, net, pretax for the quarter ending 2012-06-30 was $0.00.
- LIFEVANTAGE CORP gain (loss) on derivative instruments, net, pretax for the quarter ending 2012-03-31 was -$10.69M.
- LIFEVANTAGE CORP gain (loss) on derivative instruments, net, pretax for fiscal 2014 was $0.00.
- LIFEVANTAGE CORP gain (loss) on derivative instruments, net, pretax for fiscal 2013 was $0.00.
- LIFEVANTAGE CORP gain (loss) on derivative instruments, net, pretax for fiscal 2012 was -$6.74M.
- LIFEVANTAGE CORP gain (loss) on derivative instruments, net, pretax for fiscal 2011 was -$48.45M.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month as first filed | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month as first filed | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month as first filed | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2014-06-30 | $0.00 10-K · filed 2014-09-10 | |||||||
| 2013-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-10 | $0.00 derived: sum of 2 quarters · filed 2014-09-10 | $0.00 10-K · filed 2014-09-10 | |||||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-09 | $0.00 10-Q · filed 2013-05-09 | ||||||
| 2012-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-10 | -$10.69M derived: sum of 2 quarters · filed 2014-09-10 | -$7.54M derived: sum of 3 quarters · filed 2014-09-10 | -$6.74M 10-K · filed 2014-09-10 | -$6.74M 10-K · filed 2012-09-10 | |||
| 2012-03-31 | -$10.69M 10-Q · filed 2013-05-09 | -$10.69M 10-Q · filed 2012-05-15 | -$7.54M derived: sum of 2 quarters · filed 2013-05-09 | -$6.74M 10-Q · filed 2013-05-09 | -$6.74M 10-Q · filed 2012-05-15 | -$52.42M derived: sum of 4 quarters · filed 2013-09-12 | ||
| 2011-12-31 | $3.14M 10-Q · filed 2013-02-07 | $3.14M 10-Q · filed 2012-02-14 | $3.95M 10-Q · filed 2013-02-07 | $3.95M 10-Q · filed 2012-02-14 | -$41.73M derived: sum of 3 quarters · filed 2013-09-12 | -$51.82M derived: sum of 4 quarters · filed 2013-09-12 | ||
| 2011-09-30 | $805.00K 10-Q · filed 2012-11-08 | $804.77K 10-Q · filed 2011-11-14 | -$44.87M derived: sum of 2 quarters · filed 2013-09-12 | -$54.96M derived: sum of 3 quarters · filed 2013-09-12 | -$49.48M derived: sum of 4 quarters · filed 2013-09-12 | |||
| 2011-06-30 | -$45.68M derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | -$55.77M derived: sum of 2 quarters · filed 2013-09-12 | -$50.29M derived: sum of 3 quarters · filed 2013-09-12 | -$48.45M 10-K · filed 2013-09-12 | -$48.45M 10-K · filed 2012-09-10 | |||
| 2011-03-31 | -$10.09M 10-Q · filed 2012-05-15 | -$4.61M derived: sum of 2 quarters · filed 2012-05-15 | -$2.78M 10-Q · filed 2012-05-15 | |||||
| 2010-12-31 | $5.48M 10-Q · filed 2012-02-14 | $7.31M 10-Q · filed 2012-02-14 | ||||||
| 2010-09-30 | $1.84M 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |